Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Bonus News from MarketBeat Media Johnson & Johnson Quietly Triggers a Trend Following Buy SignalBy Thomas Hughes. First Published: 1/23/2026. 
In Brief - Johnson & Johnson pulled back into a trend-following entry after its Q4 2025 release and guidance update.
- Analysts and institutional trends support the stock's price action and point to new highs in 2026.
- Capital return and capital return growth are factors, with both reliable for the foreseeable future.
Johnson & Johnson (NYSE: JNJ), amid political noise over Trump's Greenland agenda and renewed trade-war fears, is quietly executing its healthcare strategy—growing revenue and widening margins—and positioning its stock to continue trending higher. A recent earnings release and 2026 guidance update, though strong, produced a price pullback that created a trend-following opportunity. 
What is a trend-following signal? Assuming an uptrend, as with JNJ stock, a trend-following signal happens when the price action pulls back to a trend-following indicator—such as a moving average or trend line—and then finds support there. That pattern affirms the presence of buyers, indicates a high potential rebound, and reduces downside risk for new entries. The likely outcome is that the stock resumes its steady advance and sets fresh highs in the near term. Johnson & Johnson's Healthy Business and Pipeline Underpin Stock Price Action Johnson & Johnson's Q4 results highlighted the strength of its portfolio and pipeline, with revenue up 9.1% year over year and nearly 200 basis points above expectations. The gains were driven by core strength in Innovative Medicine and MedTech, along with contributions from acquisitions. Organic revenue grew 7.1% and adjusted revenue rose 6.1%; the company expects to sustain a mid-single-digit growth pace in 2026. Margins, roughly in line with consensus, were an area of strength in the report. Adjusted earnings also met expectations and showed notable improvement versus the prior year. Adjusted earnings rose more than 20%, bolstering an already strong balance sheet and supporting the company's capital return outlook. Management's guidance was constructive—and likely conservative. The company is targeting 6.7% revenue growth and margin expansion, both above consensus. Momentum in core segments, especially with blockbusters like Darzalex, along with continued pipeline advancement, could allow the company to exceed its own guidance in the next report. Finally, the company reported positive results from several trials and submitted its OTTAVA robotic surgical system for De Novo classification. If approved, OTTAVA would create a new revenue stream with potential to grow at a high-double-digit rate for several years. Johnson & Johnson Results Align With Bullish Analyst Trends Johnson & Johnson's bullish analyst trends are unlikely to abate given the Q4 strength and outlook. As it stands, the 29 analysts tracked by MarketBeat rate this stock a Moderate Buy, and price targets are trending higher. The consensus price target implies the stock is fairly valued, with shares trading near their pre-release close, but the trend favors the top of the range—consistent with roughly 10% upside and the potential for a fresh all-time high. Institutions also accumulated shares in 2025 and early 2026, which helps limit downside risk should the stock pull back. Johnson & Johnson's dividend is another reason analysts and institutions like this stock. The dividend yields nearly 2.5% even with shares near record highs, and it is expected to grow over time. The company is a Dividend King with more than 60 consecutive years of annual increases. A payout ratio near 50% suggests modest, single-digit dividend increases can be sustained for the foreseeable future. Risks for JNJ shareholders in 2026 include ongoing talc litigation, competition from Stelara biosimilars, and execution risk tied to the OTTAVA launch. Talc litigation continues to advance after a court allowed the plaintiff's expert testimony, creating a hurdle the company can still rebut. Meanwhile, Stelara lost patent protection in 2025 and will face increasing biosimilar competition as the year progresses; Stelara sales—about 11.5% of 2024 revenue—declined more than 40% in 2025.
| 
Post a Comment
Post a Comment